Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 14, 2019

SELL
$9.54 - $14.96 $202,724 - $317,900
-21,250 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$10.31 - $14.38 $56,663 - $79,032
5,496 Added 34.89%
21,250 $297,000
Q4 2018

Feb 14, 2019

BUY
$8.63 - $12.4 $135,957 - $195,349
15,754 New
15,754 $160,000

Others Institutions Holding EIGR

About Eiger BioPharmaceuticals, Inc.


  • Ticker EIGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,966,800
  • Market Cap $418M
  • Description
  • Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...
More about EIGR
Track This Portfolio

Track Blue Crest Capital Management LTD Portfolio

Follow Blue Crest Capital Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Blue Crest Capital Management LTD with notifications on news.